IDEAS home Printed from https://ideas.repec.org/a/neo/journl/v19y2022i1p65-78.html
   My bibliography  Save this article

Value-Added Chain Of A New Pharmaceutical Product

Author

Listed:
  • Milena Filipova

    (South-West University “Neofit Rilski”, Blagoevgrad, Department of Management and marketing)

  • Yulia Nedelcheva

    (South-West University “Neofit Rilski”, Blagoevgrad, Department of Management and marketing)

Abstract

The aim of our study is to present the value-added chain for a new pharmaceutical product. Shifts in society are setting new expectations to pharmaceutical products. By critically using the results of leading researchers, we form the modern value-added chain. The results of our study determine the most complex value-added chain for a new pharmaceutical product. The requirements by competent authorities for safe, efficient and quality pharmaceutical products determine the dynamics of value-added chain steps. The safety and efficacy of a new pharmaceutical product reduce the importance of other factors such as innovative and affordable product.

Suggested Citation

  • Milena Filipova & Yulia Nedelcheva, 2022. "Value-Added Chain Of A New Pharmaceutical Product," Economics and Management, Faculty of Economics, SOUTH-WEST UNIVERSITY "NEOFIT RILSKI", BLAGOEVGRAD, vol. 19(1), pages 65-78.
    • Handle: RePEc:neo:journl:v:19:y:2022:i:1:p:65-78
    DOI: 10.37708/em.swu.v19i1.6
    as

    Download full text from publisher

    File URL: http://em.swu.bg/images/SpisanieIkonomikaupload/SpisanieIkonomika2022/6.%20MFilipova_YNedelcheva%20Value%20added%20chain%203.pdf
    Download Restriction: no
    File URL: https://libkey.io/10.37708/em.swu.v19i1.6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Radostina Yuleva, 2019. "Basic Theoretical Statements For The Competitiveness Of Small And Medium-Sized Enterprises," Entrepreneurship, Faculty of Economics, SOUTH-WEST UNIVERSITY "NEOFIT RILSKI", BLAGOEVGRAD, vol. 7(1), pages 25-35.
    2. Gittelman, Michelle, 2016. "The revolution re-visited: Clinical and genetics research paradigms and the productivity paradox in drug discovery," Research Policy, Elsevier, vol. 45(8), pages 1570-1585.
    3. Spartak Keremidchiev & Miroslav Nedelchev, 2020. "Theories Of Corporate Governance At State-Owned Enterprises," Economics and Management, Faculty of Economics, SOUTH-WEST UNIVERSITY "NEOFIT RILSKI", BLAGOEVGRAD, vol. 17(2), pages 61-71.
    4. Craig L. Garthwaite, 2012. "The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors," American Economic Journal: Applied Economics, American Economic Association, vol. 4(3), pages 116-137, July.
    5. Lalka Borisova, 2017. "Balanced Scorecard In The Organization," Entrepreneurship, Faculty of Economics, SOUTH-WEST UNIVERSITY "NEOFIT RILSKI", BLAGOEVGRAD, vol. 5(1), pages 66-76.
    6. Fernando Antoñanzas & Robert Terkola & Maarten Postma, 2016. "The Value of Medicines: A Crucial but Vague Concept," PharmacoEconomics, Springer, vol. 34(12), pages 1227-1239, December.
    7. Ralph C. Epstein & Florence M. Clark, 1934. "Industrial Profits in the United States," NBER Books, National Bureau of Economic Research, Inc, number epst34-1.
    8. Miroslav Nedelchev, 2019. "Corporate Governance of State-Owned Enterprises: The Case of Healthcare Establishments in Bulgaria," Economic Studies journal, Bulgarian Academy of Sciences - Economic Research Institute, issue 1, pages 115-123.
    9. Christopher Paul Adams & Van Vu Brantner, 2010. "Spending on new drug development," Health Economics, John Wiley & Sons, Ltd., vol. 19(2), pages 130-141, February.
    10. Raya Madgerova & Vyara Kyurova, 2014. "Definition, Characteristics And Problems Of Family Business," Economics and Management, Faculty of Economics, SOUTH-WEST UNIVERSITY "NEOFIT RILSKI", BLAGOEVGRAD, vol. 10(2), pages 97-105.
    11. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ming Liu & Sumner LaCroix, 2011. "The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries," Working Papers 201116, University of Hawaii at Manoa, Department of Economics.
    2. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.
    3. Alexandre Guimarães Vasconcellos & Carlos Medicis Morel, 2012. "Enabling Policy Planning and Innovation Management through Patent Information and Co-Authorship Network Analyses: A Study of Tuberculosis in Brazil," PLOS ONE, Public Library of Science, vol. 7(10), pages 1-10, October.
    4. Ming Liu & Sumner la Croix, 2013. "A Cross-Country Index of Intellectual Property Rights in Pharmaceutical Innovations," Working Papers 201313, University of Hawaii at Manoa, Department of Economics.
    5. Sanzenbacher, Geoffrey T. & Wettstein, Gal, 2020. "Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D," Journal of Health Economics, Elsevier, vol. 72(C).
    6. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
    7. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
    8. Milena Filipova & Yulia Nedelcheva, 2022. "Competitiveness Factors Of Pharmaceutical Manufacturer," Entrepreneurship, Faculty of Economics, SOUTH-WEST UNIVERSITY "NEOFIT RILSKI", BLAGOEVGRAD, vol. 10(1), pages 78-92.
    9. Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015. "Market size and pharmaceutical innovation," RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
    10. Milena Filipova & Yulia Nedelcheva, 2022. "Assessment Of Pharmaceutical Manufacturers’ Competitiveness," Entrepreneurship, Faculty of Economics, SOUTH-WEST UNIVERSITY "NEOFIT RILSKI", BLAGOEVGRAD, vol. 10(1), pages 59-67.
    11. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
    12. Tobias Basse & Christoph Schwarzbach & J.-Matthias Schulenburg, 2023. "Dividend policy issues in the European pharmaceutical industry: new empirical evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(5), pages 803-816, July.
    13. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
    14. Liu, Ming & La Croix, Sumner, 2015. "A cross-country index of intellectual property rights in pharmaceutical inventions," Research Policy, Elsevier, vol. 44(1), pages 206-216.
    15. Maarten Ijzerman & Lotte Steuten, 2011. "Early assessment of medical technologies to inform product development and market access," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 331-347, September.
    16. Holger Patzelt & Dean A. Shepherd, 2009. "Strategic Entrepreneurship at Universities: Academic Entrepreneurs’ Assessment of Policy Programs," Entrepreneurship Theory and Practice, , vol. 33(1), pages 319-340, January.
    17. Patzelt, Holger & zu Knyphausen-Aufseß, Dodo & Fischer, Heiko T., 2009. "Upper echelons and portfolio strategies of venture capital firms," Journal of Business Venturing, Elsevier, vol. 24(6), pages 558-572, November.
    18. Jeon, Sung-Hee & Pohl, R. Vincent, 2019. "Medical innovation, education, and labor market outcomes of cancer patients," Journal of Health Economics, Elsevier, vol. 68(C).
    19. Hoekman, Jarno & Rake, Bastian, 2024. "Geography of authorship: How geography shapes authorship attribution in big team science," Research Policy, Elsevier, vol. 53(2).
    20. Darius Lakdawalla & Neeraj Sood, 2007. "The Welfare Effects of Public Drug Insurance," NBER Working Papers 13501, National Bureau of Economic Research, Inc.

    More about this item

    Keywords

    pharmaceutical industry; step-by-step production;

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • L23 - Industrial Organization - - Firm Objectives, Organization, and Behavior - - - Organization of Production
    • L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:neo:journl:v:19:y:2022:i:1:p:65-78. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Vladislav Krastev (email available below). General contact details of provider: https://edirc.repec.org/data/feswubg.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.